

**UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF MISSISSIPPI
NORTHERN DIVISION**

GENBIOPRO, INC.

PLAINTIFF

V.

C.A. NO. 3:20-CV-00652-HTW-LRA

**DR. THOMAS DOBBS, STATE HEALTH OFFICER
OF THE MISSISSIPPI DEPARTMENT OF HEALTH,
IN HIS OFFICIAL CAPACITY**

DEFENDANTS

**DECLARATION OF THOMAS LEONARD
IN SUPPORT OF REQUEST FOR REDACTION**

1. My name is Thomas Leonard. I am an adult resident of the United States. I am over 21 years of age, and I am competent to testify to the matters set forth in this Declaration.

2. I am the Chief Executive Officer of GenBioPro, Inc. ("GBP").

3. GBP is closely-held; its stock is not offered for sale to the general public.

4. GBP and Danco Laboratories ("Danco") are the only companies currently holding FDA approvals to sell mifepristone in the United States for use in the termination of pregnancy.

5. My job responsibilities at GBP include tracking GBP's sales and revenue and determining GBP's market share for mifepristone. GBP uses proprietary methods to determine that market share, as neither GBP nor Danco make their sales data public. For instance, while many prescription drug sales are reported to, tracked by, and reported by publicly accessible data services, GBP does not report such sales and they are thus not trackable by such data services.

6. GBP's financials—including but not limited to its market share—are a closely-held secret. Nobody outside of GBP is given this information without first signing a stringent non-disclosure/confidentiality agreement, and even then only in very limited circumstances.

7. If Danco, or the general public at large, were to learn about GBP's internal estimate of its market share, the company would suffer substantial harm. More specifically, it is highly probable that either Danco or a new third-party competitor could use the information to glean how GBP's pricing and marketing strategies drive utilization of GBP's drug. Put simply, these competitors might use the fact that GBP filed a lawsuit to protect its rights to gain an unfair competitive advantage.

EXHIBIT A

8. As required under 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct.

Executed, this the 27th day of May, 2021.



THOMAS LEONARD